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Abstract
Background: Type 1 diabetes mellitus is caused by immune-mediated destruction of pancreatic b-cells leading to insulin
deficiency, impaired intermediary metabolism, and elevated blood glucose concentrations. While at autoimmune diabetes
onset a limited number of b-cells persist, the cells’ regenerative potential and its regulation have remained largely
unexplored. Using two mouse autoimmune diabetes models, this study examined the proliferation of pancreatic islet ß-cells
and other endocrine and non-endocrine subsets, and the factors regulating that proliferation.
Methodology and Principal Findings: We adapted multi-parameter flow cytometry techniques (including DNA-content
measurements and 59-bromo-29-deoxyuridine [BrdU] incorporation) to study pancreatic islet single cell suspensions. These
studies demonstrate that b-cell proliferation rapidly increases at diabetes onset, and that this proliferation is closely
correlated with the diabetic animals’ elevated blood glucose levels. For instance, we show that when normoglycemia is
restored by exogenous insulin or islet transplantation, the b-cell proliferation rate returns towards low levels found in
control animals, yet surges when hyperglycemia recurs. In contrast, other-than-ß endocrine islet cells did not exhibit the
same glucose-dependent proliferative responses. Rather, disease-associated alterations of BrdU-incorporation rates of d-
cells (minor decrease), and non-endocrine islet cells (slight increase) were not affected by blood glucose levels, or were
inversely related to glycemia control after diabetes onset (a-cells).
Conclusion: We conclude that murine b-cells’ ability to proliferate in response to metabolic need (i.e. rising blood glucose
concentrations) is remarkably well preserved during severe, chronic b-cell autoimmunity. These data suggest that timely
control of the destructive immune response after disease manifestation could allow spontaneous regeneration of sufficient
b-cell mass to restore normal glucose homeostasis.
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Introduction
Type 1 Diabetes Mellitus (T1DM) is an autoimmune disease
characterized by insulin deficiency and the loss of glycemia
control, and is caused by the T-cell mediated destruction of
pancreatic insulin-producing ß cells. It becomes clinically apparent
rather late during its chronic progressive course, and has long been
considered irreversible due to the assumption that b-cells have no
or only limited regenerative capacity and are unable to withstand
the continuing ß-cell autoimmunity. Thus, individuals diagnosed
with T1DM must rely on insulin injections, a therapy of
incomplete efficacy that comes with an impaired quality of life,
and serious long-term side effects, that can severely limit life
expectancy. Recent reports have suggested that adult b-cells might
be able to expand under certain conditions [1], and experimental
rodent models have confirmed this notion in general [2]. Such b-
cell expansion may be due to cell duplication (mitosis) of residual
b-cells [3–6] or neogenesis from putative intrapancreatic progen-
itors [7–9], or both; see [10] for review. In T1DM patients, the
potential for b-cell proliferation has been suggested by histopath-
ological findings [11], and persistent C-peptide production for
many years after diagnosis [12]. A transient remission commonly
observed shortly after T1DM onset, called the ‘‘honeymoon’’, also
suggests that b-cells temporarily recover functionally and/or in
quantity after diabetes onset [13].
Recent studies have explored the mechanisms underlying b-cell
expansion. b-cells slowly divide in adult mice and rats [14], but the
process can be accelerated temporarily under physiologic [15–17]
or pathologic conditions [3,5,6]. For instance, b-cell proliferation
rates increase during adolescence [18,19], pregnancy [17,20],
dietary manipulations [15,21] that may be further stimulated in
insulin-resistant states [22] and obesity, during organ regeneration
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cell-ablation [6]. However, no consensus has emerged regarding
the proportional roles played by b-cell mitosis or neogenesis, and
what regulates such b-cell expansion in vivo [24]. In particular, b-
cell proliferative responses during autoimmune diabetes have not
been studied in greater detail; in part because such efforts to
increase ß-cell mass have been considered futile in the face of
continued immune-mediated destruction. Other more technical
factors have limited such study, i.e. the inflammatory infiltrate
within the pancreatic islets and the scarcity of residual b-cells at
disease onset both severely compromise the microscope-based
analysis of b-cell numbers and phenotype. Thus it is unclear if
residual b-cells at disease onset are responsive to signals known to
stimulate b-cell expansion/regeneration under other circumstanc-
es. Such stimuli may be of local or systemic origin, and include
inflammation and organ repair [25,26], sensing a net b-cell loss
[27,28], increased glucose concentrations [29–32], or pathologic
levels of downstream intermediates of the glucose signaling
cascade [28,33–35], insulin deficiency [36,37], and a variety of
incretins, secreted from sources located inside and outside of the
islets [38].
Pancreas research has heavily relied on traditional techniques
such as immunohistochemistry and multiparameter immunofluo-
rescence microscopy. These methods are laborious and may suffer
from a considerable heterogeneity of the disease process in the
pancreas. Recognizing the limitations associated with the current
assessment tools we have developed complementary flow cytom-
etry approaches to measure small but significant changes in b-cell
numbers and function during autoimmune islet destruction.
Common flow cytometric techniques used to quantify (mostly
hematopoetic) cell proliferation include (i) detection of increased
nuclear DNA ahead of cell division, and Ab-mediated detection of
either (ii) proteins whose expression is closely associated with stage-
specific cell cycle progression (e.g. Ki-67 [39], phospho (p)-histone
H3 [40]), or (iii) nucleoside analogs (e.g. BrdU), which are stably
incorporated into newly synthesized DNA [41].
We sought to establish flow cytometry as a novel tool for
pancreas research that can complement prevailing advanced
microscopic techniques. Employing systematic multicolor intracy-
toplasmic (or -nuclear) staining strategies allowed us to examine
the magnitude and regulation of islet cell growth during
autoimmune diabetes. Two autoimmune diabetes models were
studied, the non-obese diabetic (NOD) mouse and the rat insulin
promoter (Rip) CD806lymphocytic choriomeningitis virus glyco-
protein (GP) bi-transgenic mouse, an inducible, experimental
autoantigen-specific diabetes (EAD) model (see Methods). We find
that the ambient glucose concentration, much more than immune
cell activity or organ injury, is the primary factor associated with b-
cell mitosis. Other-than-b-islet cell subpopulations do not exhibit a
similar glucose dependent cell proliferation.
Methods
Mice
Our cytotoxic T lymphocytes (CTL)-induced EAD model is an
inducible, autoantigen-specific diabetes model based on the Rip-
GP6Rip-CD80 bi-transgenic mouse. In this model, the ß-cell-
expressed CD80 transgene-product mediates profoundly increased
diabetes susceptibility [42], and the ß-cell GP-protein provides a
molecularly and immunologically well-defined target molecule
suitable to sensitize antigen-specific CTL responses and diabetes
development (GP, [43]). While naı ¨ve Rip-CD80+GP+ mice do not
develop spontaneous diabetes, antigen-specific sensitization or
transfusion of in vitro activated, monoclonal GP-specific, TCR
transgenic CTL (p14 strain [44], Rag1-null) results in b-cell-
specific autoimmune islet destruction and diabetes (termed EAD)
[45]. Importantly, disease process kinetics can be controlled by the
potency of GP-specific vaccinations or by controlling the
transfused CTL number and activation state. The insulinoma-
prone Rip-Tag2 transgenic mouse strain [46] was obtained from
the repository of the Mouse Models of Human Cancer
Consortium, NCI Frederick, MD, and was used as a source of
tumorigenic b-cells. NOD mice (NOD/ShiLtJ) and C57BL/6J
mice were purchased from Jackson Labs, Bar Harbor, ME, and
either used for experiments or were further bred in house. All mice
were maintained at the Division of Veterinary Resources, NIH, in
accordance with the guidelines set forth by the Committee on the
Care and Use of Laboratory Animals on a protocol approved by
the IACUC of the National Institute of Diabetes, Digestive, and
Kidney Diseases (NIDDK).
T cell purification and in vitro activation of b-cell specific
CTL
CD8+ T cells were purified from GP TCR trangenic (p14-
strain, Rag1-null) by immunodepletion of I-A
b, CD11b, and
NK1.1 -expressing spleen and lymph node cells. The prepared
lymphocytes were 86–95% CD8+. Purified CD8+ P14 T cells
(0.5*10
6/cm
2) were stimulated for 3–4 days in the presence of
antigen-presenting cells (APC) preloaded with its agonist peptide
(GP aa 33–41 at 0.1 mM for 1 h,) at a T/APC ratio of 20. These
APC were C57BL/6-derived pancreatic fibroblast cell lines, that
had been cultured in DMEM 10% FCS supplemented with 2 ng/
ml recombinant murine IFNc to upregulate MHC class I
expression for the final 1–2 days prior to T cell co-culture. 48 h
after T cell activation, cultures were supplemented with IL-2
(2 ng/ml). On day 3 of culture virtually all viable cells had an
activated phenotype and by flow cytometry were .98% CD8 and
TCR-transgene positive (data not shown).
Diabetes induction and diagnosis
We initiated ß-cell-specific islet destruction in Rip-CD806Rip-
GP bi-transgenic mice at a median age of 10.3 weeks by adoptively
transferring (i.v.) CTL (10
6/mouse) as described above. Fibroblast-
stimulated d3CTL typically mediate a slowly progressive ß-cell
destruction in the (CTL-induced) EAD model (diabetes onset after
53+/29 d). NOD mice were allowed to spontaneously develop
diabetes (diabetes onset for both diabetes models is shown in
Supporting Information Figure S1). Prior to the expected
time of diabetes onset, non-fasted mice were checked daily for
urine glucose, and diabetes was confirmed by blood glucose (BG)
readings above 13.3 mM (240 mg/dl) on two consecutive days.
The term pre-diabetes has been used rather broadly, randomly
encompassing non-diabetic mice with no attempt to predict the
stage of diabetes development more precisely (e.g. using
histopathology or glucose tolerance testing).
Induction of diabetes control
We used three different ways to temporarily or perma-
nently restore normoglycemia with or without control of
autoimmunity:
1. CD8 T lymphocyte immunodepletion: CD8 T lympho-
cyte-depleting mAb (anti-CD8, clone YTS169, [47]) was
injected i.p. twice 48 h apart (500 and 200 mg/mouse, respec-
tively). This treatment led to gradual diabetes remission and
normoglycemia (urine glucose-negative and BG,,11.1 mM
[200 mg/dl]), which lasted for at least 7 consecutive days
in 6 of 9 mice. Prior experience has shown that remissions
b-Cell Replication in Diabetes
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hyperglycemia within 1–2 weeks, i.e. when the depleted T cells
recover.
2. Insulin pellets: Exogenous insulin was administered via
insulin-releasing pellets (about 1 mm64 mm in size releasing
approx 0.1 U/24 h, LinShin Canada Inc., Toronto, Canada).
Under short-term anesthesia, the left flank skin was punctured
using a 14G needle, and a pellet applicator was used to place
usually a single insulin pellet s.c. Normal BG levels were
typically restored within 12 h, and generally ‘‘normal’’ BG
concentrations were observed, typically for more than a week.
In some cases, insulin pellets were surgically removed after 3
days of normoglycemia, which instantly led to recurrent
hyperglycemia.
3. Islet transplantation: C57BL/6 islets were used to restore
normoglycemia in congeneic Rip-CD80+GP+ mice. We have
previously established that these wild type islets do not
constitute a target for autoreactive T cells, since they lack
both the costimulatory CD80 molecule and the GP autoanti-
gen. Such islet grafts permanently cure diabetic Rip-
CD80+GP+ mice with no histological evidence of congeneic
graft rejection. Islets were transplanted under the left kidney
capsule using a retroperitoneal approach. Briefly, under
isoflurane anesthesia, the left kidney was exposed, and a pouch
was formed between the capsule and the kidney parenchyma of
about 7612 mm size. 300–400 islets (cultured overnight in
standard culture medium: DMEM 4.5 g/L Glucose, 10%
FCS) were transferred into a sterile silicon laboratory tubing
(30 cm length, 0.51 mm diameter, Silastic, Dow Corning,
Midland, MI). By a brief spin, islets were collected at one end
of the tubing, which was then slipped into the kidney pouch,
and the islets were deposited. The pouch was sealed using tissue
glue (Vetbond, 3M, St. Paul, MN). The wound was closed, and
pain relief was provided for 2 days (banamine 1.5 ug/g BW
twice daily). BG levels dropped to normal levels within several
hours postoperatively. Mice remained normoglycemic for the
entire experiment; that is the mice had no glucosuria and
random BG values were essentially normal (7–8 mM, see
Supporting Information Table S1).
Islet isolation
Pancreatic islets were isolated by standard techniques, with
minor adaptations. Briefly, pancreata from naı ¨ve mice or from
mice at various stages of autoimmune diabetes development,
were inflated via bile duct cannulation and retrograde pancreatic
duct injection of 3–4 ml of ice-cold collagenase type XI
(1 mg/ml in HBSS, Sigma, St. Louis, MO). Following digestion
(37uC, 14 min), pancreata were broken apart by aspirating
through a 14G needle, then filtered through a metal strainer
(0.8 mm). Pancreas suspensions were then subjected to buoyant
density gradient centrifugation (14–15% Optiprep, Accurate
Chemicals, Westbury, NY), followed by handpicking of all
discernible islets. Upon removal of islets, the remaining viable
pancreatic cells were collected and termed the islet-depleted
fraction, containing sub-islet-sized endocrine clusters and single
endocrine cells.
Islet dissociation and hormone staining
Isolated islets were dissociated into single cell suspensions after
washing in 2 mM EDTA/PBS, then incubating for 10 min at
ambient temperature in Ca
2+ free PBS supplemented with 0.025%
trypsin, and finally by careful pipeting. Dissociated islet cells
prepared from prediabetic or diabetic mice were stained for
CD45, to identify infiltrating lymphocytes, followed by washing,
and immediate single step fixation and permeabilization (4% PFA,
Electron Microscopy Sciences, Hatfield, PA, 0.1% saponin, Fluka
Chemicals, Buchs, Switzerland, in PBS, 30 min room tempera-
ture). After removing PFA by washing in 0.1 saponin/1% BSA/
PBS, islet cells were stained intracytoplasmically for 25 min with
Ab to insulin (1:300, guinea pig, DAKO, Carpinteria, CA). For
multiple hormone stainings, glucagon and somatostatin mouse
IgG1 mAb (respectively K79bB10, Sigma, and SOM018, Ab core
facility, Beta Cell Biology Consortium [BCBC], Denmark) were
used in conjunction with Zenon (pre)labeling technology for
mouse IgG1 (AlexaFluor488 and Pacific Blue conjugates,
respectively, Invitrogen, Carlsbad, CA). Highly cross-absorbed,
second-step polyclonal Ab, anti-guinea pig-Cy5 was from Jackson
ImmunoResearch (West Grove, PA). After the final wash in
1%BSA/saponin, cells were post-fixed in 1% PFA and acquired
using a CyAn ADP flowcytometer and Summit V 4.3 Software
(Beckman-Coulter, Miami, FL). Electronic gating was set to
include viable cells on the basis of forward scatter vs. side scatter
while doublet-exclusion gating was applied to eliminate non-
dissociated islet cell couplets on the basis of pulse width patterns
for each islet cell subset (color). The numbers of b-cells of all
acquired and analyzed samples (2–3 samples per mouse islet
preparation) ranged from 4,021–37,213 for naı ¨ve, and from 754–
18,950 for diabetic mouse islets.
Quantitative DNA staining
Quantitative DNA staining (5 uM, Vybrant DyeCycle Violet,
Invitrogen) was used to enumerate cells with increased DNA
content, indicative of cell cycle S- or G2/M phase. Vybrant
DyeCycle violet staining reagent was chosen for its quantitative
DNA staining properties (DNA-binding induces a linear increase
in fluorescence), and spectral characteristics using a violet laser
(excitation/emission were 405 nm and 450620 nm, respectively)
to avoid overlap with other fluorescent dyes excited by different
lasers in multicolor applications. To ensure single cell analysis, a
doublet-exclusion strategy was applied involving linear signal area
versus signal peak (height) gating in the presence of a quantitative
DNA stain and the flow cytometer’s hydrodynamic sample stream
focusing provisions. The algorithm underlying electronic doublet
exclusion strategies is well established [48], taking advantage of
couplet orientation during hydrodynamic focusing (i.e. when
sheath fluid forces the sample stream through the nozzle to the
laser intersection point). While doublet exclusion gating eliminated
nearly all double hormone positive cells (a ,20 fold reduction), it
did not significantly alter the relative endocrine cell frequencies
and the calculated cell ratios (Supporting Information Figure
S2). As nuclear staining intensity doubles when proliferating cells
transition through the phases of the cell cycle, the G0/G1 subset’s
coefficient of variation (CV, representing the normalized
measure of dispersion of single event signals) becomes critically
important to distinguish the G0/G1 to S-Phase transition.
Typically, cytoplasm-stripped, isolated nuclei are used for cell
cycle analysis, since purified nuclei exhibit a smaller CV.
However, identifying ß-cells in a heterogeneous islet cell
suspension requires intracytoplasmic insulin staining, resulting in
a greater CV due to the increased autofluorescence and
cytoplasmic fluorescence background. Therefore, to minimize
distorting early S-Phase cell counting, we arbitrarily defined the
linear fluorescence intensity of nuclear DNA in proliferating b-
cells as §1.4-fold of the G0/G1 mean linear fluorescence intensity.
Thus, the 1.4-fold mean linear G0/G1 fluorescence cutoff while
arbitrary, estimates the number of cells progressing through S-
Phase until mitosis completion.
b-Cell Replication in Diabetes
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BrdU (Fluka Chemicals) was either supplied continuously for 7
days in drinking water (1 mg/ml), or injected i.p. The latter
involved either 1 injection (1.5 mg/mouse), or daily injections on
three consecutive days prior to islet isolation (first injection 1.5 mg,
and 1 mg each for the following 2 days). BrdU staining for flow
cytometry of fixed dissociated islet cells required pre-treatment
with DNase I (0.1 mg/ml [approx. 57 Kunitz Units/ml], Sigma,
in HBSS/0.1% saponin (30 min at 37uC), followed by staining for
25 min at 4uC with anti-BrdU mAb (clone PRB-1 conjugated to
Alexa Fluor 647, Invitrogen).
Statistical analysis
An independent Student’s T Test (one-tailed) was chosen to test
the significance of increases or decreases between data sets
(endocrine cell ratios), and the linear regression analysis was
described using the Pearson product moment correlation coeffi-
cient, r.
Results
Flow cytometry demonstrates that autoimmune diabetes
stimulates ß-cell cycle progression
Reasoning that adapting flow cytometry-based techniques to
pancreas research would greatly facilitate a more quantitative
analysis of b-cell proliferation in islets undergoing autoimmune
destruction, we have developed protocols to isolate islets from
naı ¨ve and diabetic mice, dissociate them into single cells, and
identify their endocrine cell lineage by co-staining for intracyto-
plasmic insulin, glucagon, and somatostatin (data not shown).
Supporting Information Figure S3 illustrates electronic
gating strategies to identify islet b-cells, based sequentially on
CD45+ hematopoetic-lineage cell exclusion, insulin-staining, and
eliminating not fully dissociated islet cell clusters using the
hydrodynamic focusing-based, electronic doublet exclusion gating
strategy on nuclear fluorescence. As illustrated in Figure 1A,w e
determined the fraction of cells with increased DNA content
(ranging from less than 1% to more than 10%) using a quantitative
DNA-intercalating dye, and electronically-gating on b-cells from
healthy, naive (left), and recently diabetic mice (middle), and
among Rip-Tag2 transgenic animals that develop insulinomas
(right) [46]. Quantitative analysis (Figure 1B) demonstrates that
islet cells isolated from newly diabetic EAD mice had a higher
proportion of b-cells with increased DNA content (3.9%, range
2.5–5.7, n=20) compared to naı ¨ve mice (1.6%, range 0.8–2.4%,
n=25), suggesting that diabetic mice have a greater proportion of
b-cells with ongoing DNA synthesis and cell cycle progression.
Expectedly, tumor-prone Rip-Tag2 transgenic mice, when tested
well before they developed clinical symptoms of (transgene-
mediated) insulinomas, regularly showed a substantially increased
proportion of b-cells with the increased DNA content (11.2%,
range 7.4–14.5, n=16). Evidence supporting increased b-cell cycle
progression at diabetes onset was not unique to our CTL-induced
EAD model; we found similar results using islets isolated from
spontaneously diabetic NOD mice (6.2%, range 4.0–7.3,
Figure 1B). Pre- or non-diabetic NOD mice of a comparable
age but with incompletely characterized glucose tolerance had a
somewhat increased proportion of b-cells with elevated DNA
content (2.9%, range 1.8–4.4). Importantly, in rodent models of
both autoimmunity and ß cell tumor development, we found
increased DNA content only in b-cells and not in a-cells
(Figure 1B inset), based on glucagon staining and a comparable
gating strategy. While the DNA content analysis for determining
proliferation enjoys the important advantage of not having to label
tissue in vivo, the technique does suffer from technical and/or
biological limitations. These potentially confounding factors
include that: (1) DNA is partially degraded in the early stages of
islet cell apoptosis, which may occur during islet inflammation or
the islet isolation process, (2) the S-Phase cell DNA quantification
requires establishing a somewhat arbitrary cutoff, (3) dysfunctional
islet cells may be arrested in the G2/M phase after completing S-
phase but before they undergo cell division, and (4) doublet
exclusion efficacy may vary. Cellular uptake of the nucleoside
analog BrdU during S-Phase transition would, unlike DNA
content, likely be more stringent in labeling proliferating cells,
but the technique does not label G2/M-Phase cells, and has
further limitations. For instance, if BrdU is given some time before
islet isolation, the amount incorporated into DNA reflects the
cumulative history of cell cycles completed during the BrdU
exposure. Consequently, BrdU-labeling experiments (especially
those in which the BrdU was dosed some time before euthanasia)
cannot distinguish between endocrine cell replication and
progenitor cell replication followed by later differentiation into
an endocrine phenotype. Hence, we have used the term
‘‘proliferation’’ or ‘‘replication’’ more broadly to accommodate
both possibilities.
BrdU+ ß-cell detection by flow cytometry and ß-cell DNA
content analysis yield comparable results
In accordance with numerous studies using flow cytometry to
detect BrdU-labeled hematopoetic cells, Figure 2 demonstrates
the feasibility of this approach using dissociated islet cells (see
Supporting Information Figure S2 illustrating the gating
strategy applied to islet cell BrdU staining). Analysis of 8–10 week-
old WT mice given continuous BrdU for 7 days in their drinking
water labeled just 8.7% of their b-cells (Figure 2). In contrast,
age-matched Rip-Tag2 transgenic mice incorporated BrdU in
more than half their b-cells during the same labeling period. The
BrdU uptake in insulinoma-prone mice was b-cell specific; i.e.
both WT and insulinoma-prone mouse islet a- and d-cells
incorporated very little BrdU. However, we found that endothelial
cells, and perhaps other islet cell subsets, markedly expanded
during insulinoma formation (data not shown), which accounts for
the increased BrdU incorporation present in non-endocrine islet
cells (Figure 2, lower panel, lower right quadrants). We also noted
the 2-fold increase in proliferating somatostatin-positive d cells in
the Rip-Tag2 transgenic mice, but we did not further explore the
significance of this finding.
For the study of diabetic mice, BrdU via drinking water is
inappropriate because of the expected increased BrdU-uptake due
to the diabetes-associated polydipsia. We therefore injected the
BrdU i.p. to pulse-label islet cells, and as expected found a
substantially lower percentage of labeled endocrine cells (0.42%,
Figure 3A) compared to the 7d-drinking-water continuous
labeling technique (8.7%). We can suggest at least three
explanations for labeling fewer cells using the pulse-labeling
technique. One, BrdU labeling during DNA synthesis is
cumulative because the label is retained by daughter cells even
when they return to quiescence after cell division. Two, BrdU
availability differs when the agent is given in drinking water or by
i.p. injection; after a bolus injection, BrdU half-life is less than two
hours [49]. Three, somewhat older WT mice (,20 wks) were used
in the pulse-labeling experiment to appropriately match the
generally older EAD mice at diabetes onset (Figure 3A, see also
Methods and Supporting Information Figure S3), and
advanced mouse age has previously been shown to correlate with
decreased b-cell BrdU uptake [14]. Thus, the BrdU studies using
diabetic mice support the conclusions drawn using DNA content
b-Cell Replication in Diabetes
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diabetic mice have a substantially higher frequency of BrdU+ b-
cells (9-fold). To directly compare DNA content and BrdU
labeling assays for ß cell mitotic activity, we studied individual
mouse islet cells in a split sample approach. As shown in
Figure 3B, we observed a tight correlation whether we studied
naı ¨ve mice, or those with diabetes or incipient insulinomas
(r=0.88). To further correlate increased DNA-content with other
markers of cell cycle progression we stained for phospho (p)-
histone H3 [40] and Ki-67 [39]. Supporting Information
Figure S4 demonstrates the feasibility of b-cell staining for Ki-67.
The cell cycle associated protein Ki-67, whose function is still
poorly understood, is generally expressed during the active cell
cycle (G1 through M-Phase) [39]. Ki-67 detection correlated
incompletely with increased DNA-content, as has been observed
in islet-infiltrating lymphocytes, and in a b-cell tumor line (Min6,
data not shown). The incomplete correlation may result from
previously discussed limitations of the DNA-content assay and/or
from Ki-67’s variable expression density during the cell cycle. We
also attempted to stain b-cells directly ex vivo for the M-Phase-
specific marker p-histone H3, typically present in a small minority
of proliferating cells, but if such cells exist, our system was
insufficiently sensitive to detect them (Supporting Information
Figure S4).
Diabetic mouse b-cells undergo regulated proliferation in
situ, and maintain insulin expression during replication
We compared flow cytometry based BrdU+ b-cell frequencies
with conventional histological techniques used to enumerate
BrdU+ b-cells. Table 1 illustrates that BrdU+ b-cell numbers
Figure 1. Assessment of b-cell replication by quantitative staining of nuclear DNA and multicolor flow cytometry. Purified islets from
naı ¨ve and diabetic EAD and NOD mice, and insulinoma-developing Rip-Tag2 Tg mice were dissociated into a single cell suspension, then were fixed
and stained for insulin (Ins) and glucagon (Gcg). Nuclei were stained using a quantitative nuclear dye (Vybrant DyeCycle violet). A: Nuclear DNA
staining profiles of gated Ins+ b-cells. The range of different frequencies of DNA
hi b-cells from groups of mice is shown. These were non-diabetic,
naı ¨ve (range 0.8–1.9), diabetic EAD (range 2.5–5.7), and Rip-Tag2 transgenic mice (range 7.4–14.6). The lower panel represents a magnified y-axis
range to better illustrate the DNA
hi b-cells. B: Statistical analysis of increased b-cell DNA content displayed as percentage of overall Ins+ cells
(mean6SE): EAD (naı ¨ve, 1.560.2, n=15; and CTL-induced pre-diabetic, 2.160.2, n=12; and diabetic, 3.960.3, n=20); NOD (pre-diabetic, 2.960.2,
n=13; diabetic, 6.260.5, n=6), and Rip-Tag2 (WT, 1.660.1, n=25; transgenic, 11.260.5, n=16). Significance levels: (*) p=0.026, and (***) p,0.0001.
The inset depicts a similar DNA content analysis on Gcg+ a-cells of EAD and Rip-Tag2 mice, showing no detectable difference in a-cell DNA content
among mice.
doi:10.1371/journal.pone.0004827.g001
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comparable using both techniques, further validating our novel
flow cytometric approach. We sought to rule out the possibility
that BrdU incorporation might be explained by stress-induced
DNA damage/repair or cellular dysfunction in the highly
inflammatory environment at diabetes onset. We found that single
dose BrdU-labeled diabetic mouse ß cells display a homogenous,
bright, and nuclear BrdU immunofluorescence, strongly suggest-
ing that BrdU incorporation indeed happened during S-phase
(Supporting Information Figure S5, and Supporting
Information – Methods S1). Interestingly, we observed several
colocalized BrdU-positive b-cell pairs or small clusters by confocal
microscopy suggesting that these cells did undergo cell division in
situ within the 3 day BrdU pulse-labeling period (Supporting
Information Figure S6). Further, we tested if b-cells incorpo-
rate BrdU during S-Phase but did not complete cell division, a
process known as endoreduplication [50]. Endoreduplication
results in cells maintaining enlarged nuclei that contain (BrdU-
labeled) DNA in the amount of 4N or greater. A closer
examination by immunofluorescence microscopy of pancreatic
sections from diabetic mice however, did not reveal differences in
the average b-cell nuclear cross-sectional area when BrdU+ nuclei
were compared to neighboring BrdU- b-cells (Supporting
Information Figure S7), thus arguing against a prominent role
for b-cell endoreduplication during autoimmunity. Using flow
cytometry we also determined if b-cells down-regulated their
insulin content during cell cycle progression. Comparing b-cell
mean insulin fluorescence intensity (an estimate of cytoplasmic
insulin content) in cells separated for low DNA-content (DNA
lo or
<2N) and DNA
hi (.2N), we found comparable insulin staining
intensity in diabetic EAD (DNA
hi:DNA
lo=1.09, n=15), diabetic
NOD mice (1.02, n=5), and tumor-developing Rip-Tag2 mice
(1.08, n=18). Thus, b-cells appear to maintain their insulin
content during replication.
b-cell proliferation at autoimmune diabetes onset is
regulated by BG concentrations
The methodology to measure islet cell proliferative activity
allowed us to uncover potential forces underlying its regulation at
diabetes onset. We sought to distinguish metabolic cues stimulat-
ing ß cell replication (most obviously severe hyperglycemia) from
local factor(s) present during organ injury and/or chronic
inflammation. To differentiate these mechanisms, we restored
normoglycemia in CTL-induced EAD diabetic mice in various
ways designed to supply insulin by either the regenerating
endogenous ß-cells (afforded by deleting the ß-cell specific CTLs),
or entirely from extrapancreatic sources (continuously releasing
insulin-pellets, or congeneic islet grafts). Because the primary,
CTL-recognized autoantigen in the EAD model is the b-cell
transgene-expressed GP protein, we assumed that neither
continuous exogenous insulin, nor congeneic (but non-transgenic)
islet grafts would significantly alter the inflammatory environment
or the anti-GP autoimmune response in the pancreas during the
short 4–7 day course of the experiments.
Figure 4A illustrates how hyperglycemia resolved as a result of
the different treatments (upper panel, Supporting Information
Table S1 provides the treatment group’s average BG concentra-
tions recorded during the 3-day BrdU labeling period), and
exemplifies the concomitant detection of BrdU uptake by
infiltrating leucocytes (middle panel) or non-lymphocytic islet cell
Figure 2. Detection specificity of multiparameter flow cytometry of continuously in vivo BrdU-labeled islet cells. Mice aged 7–9 weeks
were given BrdU at 1 mg/ml in their drinking water continuously for 7 days. Islets were isolated, dissociated, and 4-color stained for insulin (red),
glucagon (blue), somatostatin (green), and for incorporated BrdU. BrdU incorporation (x-axis) was plotted for the endocrine islet cell subsets from
naı ¨ve, C57BL/6 (top panel), and insulinoma-developing yet non-symptomatic Rip-Tag2 Tg mice. Percentages indicate the relative frequency of BrdU-
stained, single cells among the particular endocrine subset identified by hormone staining. Note that depending of the stage of insulinoma
development, the frequency of glucagon+ a-cells and somatostatin+ d cells are correspondingly reduced among all islet cells acquired from purified
islets of insulinoma carrying mice.
doi:10.1371/journal.pone.0004827.g002
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impact on endogenous b-cell proliferation. Exogenous insulin (s.c.
pellets or islet-transplantation) restored normoglycemia in every
mouse, whereas depleting CD8+ T cells transiently halted direct
CTL-mediated b-cell killing so gradually restored normoglycemia
in the majority of diabetic mice (responders), with remissions
typically lasting for more than one week. Regardless the treatment
(T cell depletion by anti-CD8 mAb, exogenous insulin by s.c.
insulin pellets, or islet transplantation), restoring normoglycemia to
diabetic mice profoundly blunted the increased b-cell proliferation
observed in newly diabetic, hyperglycemic mice. In fact, using our
CTL-induced EAD model, we found a robust correlation (r=0.70)
between b-cell proliferation (BrdU pulse-labeled for 3 days prior to
islet isolation) and the average random BG level during the same
Figure 3. Single-pulse BrdU-labeled b-cells are more frequent in diabetic mice, and correlate with ß-cell DNA-content
measurements. Naı ¨ve and diabetic mice around 20 weeks of age received a BrdU injection (10 mg/ml at 2.5 mg/mouse, i.p.). Islets were isolated
the following day and 5-color stained (3-hormones, CD45+ leucocytes, and incorporated BrdU). A: Representative example of a naı ¨ve (top panel), and
a newly diabetic CTL-induced EAD mouse (bottom panel). BrdU-staining is shown on the right panel, while isotype/fluorochrome controls are shown
on the left. Note that BrdU incorporation (right panels) upon short-term exposure in naı ¨ve islets b-cells is very low, but increases in diabetic mice. B:
Correlation plot between BrdU pulse-labeling and the frequency of increased DNA content among islet b-cells. Each symbol represents islets of a
single mouse, aliquoted for independent staining of BrdU and DNA content. Three different groups of mice were tested: Rip-CD80+GP+ (naı ¨ve, open
square; and diabetic, closed circles), and insulinoma-developing Rip-Tag2 mice (open triangles). Correlation coefficient r=0.88; 95% confidence
interval (dashed lines).
doi:10.1371/journal.pone.0004827.g003
Table 1. Blood glucose selectively controls ß-cell proliferation in islets of diabetic mice.
naı ¨ve diabetic
BrdU -label: 1 d
a BrdU -label: 3 d BrdU -label: 1 d BrdU -label: 3 d
(n) BrdU+ (%)
b (n) BrdU+ (%) (n) BrdU+ (%) (n) BrdU+ (%)
IF
c 2 0.4 2 0.5 2 1.8 4 5.5
FCM 4 0.2 7 0.1 8
d 2.3 14
d 5.7
aBrdU-labeling by injection (i.p.), either 1 day (1 d), or on 3 consecutive days (3 d) before pancreas harvest.
bpercentage of BrdU+ cells among insulin+ cells.
cimmunofluorescence microscopy scoring of § 47 individual islets or small endocrine clusters of at least 2 spatially separated pancreas sections per mouse. Total b-cells
scored: (naı ¨ve mice: 1,830; diabetic mice: 944)
dmice analyzed include islets in Figure 3, and Table 2, respectively.
doi:10.1371/journal.pone.0004827.t001
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randomly assigned for treatment groups to normalize BG levels, followed by BrdU pulse labeling (3 doses indicated by arrows of 1.5, 1.0, 1.0 mg/
mouse i.p. over the final 3 days of the experiment), and islet cell analysis by flow cytometry. A: Treatment regimen, expected and exemplified results
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by the BG level was further emphasized in mice that were not
restored to normal BG levels (non-responders) by the anti-CD8
antibody treatment; in such mice with persistent hyperglycemia, b-
cell proliferation remained elevated (8.062.3%, n=3, data not
shown). This also argues against the anti-CD8 antibody causing an
inhibitory or otherwise toxic effect on b-cell proliferation. Most
importantly, residual b-cells remained responsive to changes in BG
levels. For instance, if we restored normoglycemia using insulin
pellets and thereby decreased b-cell proliferation, removing the
pellets rapidly resulted in both hyperglycemia and increased b-cell
proliferation (Figure 4B, ‘‘pellet-rem’’).
Our data suggest that hyperglycemia, rather than local
inflammatory processes, was primarily responsible for increased b-
cell proliferation at diabetes onset. We further tested this hypothesis
by comparing the mitotic response of b-cells within islets and those
found in extra-islet endocrine tissue (termed sub-islet sized
endocrineclusters). Theseendocrinecellsmaybemoreimmediately
targeted and therefore more vigorously attacked by b-cell-specific
CTL, an assumption based on histological findings. That is, we
invariably find inflammatory cells in these small clusters while at
diabetes onset, CTLs have invaded large individual islets to a
variable extent. Indeed, consistent with the hypothesis that BG
levels regulate b-cell replication in autoimmune diabetes, and using
the same mice shown in Figure 4B, we observed virtually identical
proliferative responses to therapeutic normoglycemia in residual b-
cells found in sub-islet-sized endocrine clusters, compared to those
found in large islets (Figure 5). While we believe these small
endocrine clusters comprise an anatomical compartment separate
from traditionally recognized large islets, they could also represent
over digested or fragmented large islets.
Spontaneously diabetic NOD mouse b-cell proliferation
was similarly controlled by BG concentrations
We also measured the b-cell proliferation rate in the commonly
studied NOD mouse, a spontaneous autoimmune diabetes model.
As shown in Figure 6, b-cells from newly diabetic NOD mice
exhibited increased proliferation (5.560.9% at disease onset up
from 0.960.3% of randomly selected non (or pre)-diabetic NOD
mice, Figure 6, left panel). This mitotic activity largely decreased
to 1.560.5% following sustained exogenous insulin-induced
normoglycemia (insulin-pellet). Overall, NOD mouse b-cell
proliferation rates also correlated well with pre-euthanasia BG
levels (Figure 6 right panel, r=0.78). Interestingly, while
restoring normal BG concentrations in our mice with CTL-
induced diabetes (EAD model) rapidly restored normal b-cell
replication rates, NOD mouse b-cell proliferation displayed a
delayed response to insulin treatment (Figure 6, right panel, n=3
grey triangles). That is, NOD mouse b-cell proliferation rates did
not decrease until normal blood concentrations were restored for
3–4 days (Figure 6, hatched open bar, open diamonds, n=6).
The few EAD model mice that failed treatment to normalized BG
levels following exogenous insulin (pellets) and anti-CD8 antibody
injections (Figure 4C, 6, and data not shown), presumably
because they had lost too many b-cells prior to treatment, also
maintained increased b-cell proliferation. More interestingly, short
term insulin replacement therapy in diabetic NOD mice reversed
hyperglycemia, yet regularly failed to promptly normalize b-cell
proliferation (Figure 6, pellet, early). To restore lower b-cell
proliferation rates to diabetic NOD mice required several days of
insulin-induced euglycemia (Figure 6, pellet, late). Taken
together, b-cell proliferation rates generally correlated well with
recent BG concentrations as objectively quantified using flow
cytometry analysis.
Systemic BG concentration does not control proliferation
of islet cells other-than-b-cells in autoimmune diabetes
Mice with recent-onset autoimmune diabetes harbor a multi-
tude of intra-islet cells that are phenotypically and functionally
different. These include abundant leukocytes, reflecting the
disease’s inflammatory nature, endocrine cells other than b-cells
(e.g. a- and d cells), and other non-endocrine cells, including
endothelial cells. We asked what effect the chronic organ injury
and the inflammatory environment might have on these cell
subsets in CTL-induced EAD mice. Using incorporated BrdU as
assessed by flow cytometry, we examined how these various major
are illustrated in columns. b-cell BrdU incorporation was increased in the presence of untreated hyperglycemia (lower panel). Note that both the
abundance and BrdU incorporation of islet infiltrating CD45+ leucocytes was essentially unchanged among treatment groups (middle panel). B:
BrdU-uptake of islet b-cells is controlled by BG levels. Groups of treated diabetic mice (no℞, n=8; anti-CD8 mAb, n=6; s.c. insulin pellet, n=4; ins-
pellet removed, n=3; islet-Tx, n=7) were compared to age-matched, naı ¨ve mice (n=7). Results are shown as mean6SE, with the following
significance levels: (*) p,0.05, (**) p,0.01, and (***) p,0.001. C: Correlation plot between the final 3-day average random BG readings (x-axis) and
the frequency of BrdU+ islet b-cells (y-axis). Each symbol represents a single mouse, and all mice, regardless of treatment group are included.
Correlation coefficient r=0.70; 95% confidence interval (dashed lines).
doi:10.1371/journal.pone.0004827.g004
Figure 5. BrdU incorporation of b-cells in small pancreatic
endocrine cell clusters also corresponds to BG concentrations.
Sub-islet sized clusters, often thought to be recently differentiated and/
or proliferated endocrine cells were examined for BrdU uptake. The
same treatment groups as in Figure 4B were analyzed and displayed
accordingly. Results are shown as mean6SE, with the following
significance levels: (*) p,0.05, (**) p,0.01, and (***) p,0.001.
doi:10.1371/journal.pone.0004827.g005
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Table 2,o n l yb-cells responded to hyperglycemia by substantially
increasing replication rates, as estimated by BrdU incorporation,
and then decreased that proliferation back to baseline following the
return to normal BG levels. In contrast, none of the other endocrine
or non-endocrine islet cell subsets exhibited such dramatic, BG
concentration-dependent changes. The slightly increased non-
endocrine cell proliferation rates we observed (6–10 fold over naı ¨ve
controls) did not display the same glycemia-dependence. Focusing
on specific cell types, a- and d-cell replication rates remained very
low and of unclear significance at diabetes onset (Table 2), Indeed,
the apparent small proliferation rate changes were evident using
BrdU-labeling only, since such changes fall below the DNA-content
technique’s sensitivity threshold (Figure 1, inset). We have
generated data suggesting that pancreatic a-cell numbers decrease
by more than 3-fold in mice with recent onset diabetes (data not
shown), and have speculated that this a-cell loss is an adaptive
process, secondary to b-cell destruction and islet regenerative
activity. It is therefore possible that a slightly increased a-cell
proliferation reflected recovery of the a-cell compartment, and a-
cell numbers further normalized after restoration of normoglycemia
through a-cell replication (Table 2),. Since the rate of cell death
and or endocrine cell differentiation from progenitor cells is
unknown, we must emphasize that proliferation rate changes do
Figure 6. Glycemia regulates b-cell proliferation in spontaneously autoimmune diabetic NOD mice. A: BrdU uptake by residual b-cells of
NOD mice is controlled by BG levels. Newly diabetic NOD mice were randomly treated with: no℞, n=8; exogenous insulin (pellet) and BrdU labeled
day1–3 (early), n=3, crosshatched grey bar, or BrdU labeled day 4–7 (late), n=6, hatched; insulin pellet treated mice that did not restore
normoglycemia (prim. fail.), n=4, hatched grey bar, and were compared to pre-diabetic NOD mice, n=3, open bar. Results are shown as mean6SE,
with significance levels: (*) prediabetic: p=0.016, and insulin pellet (late): p=0.0051, respectively. B: Correlation plot as in Figure 4C. Each symbol
represents a single mouse, and all mice, regardless of treatment group are included. Correlation coefficient r=0.78; 95% confidence interval (dashed
lines). Note, that NOD mice that restored normoglycemia upon insulin pellet, and were immediately BrdU labeled (pellet early) maintain increased b-
cell proliferation. These mice are shown in the plot (X) but were omitted from correlation coefficient calculation.
doi:10.1371/journal.pone.0004827.g006
Table 2. Blood glucose selectively controls ß-cell proliferation in islets of diabetic mice.
naı ¨ve Diabetes Diabetes rx’d Diabetes rx’d
(n=7) no treatment, n=7 +islet Tx, n=7
a +s.c.2ins. pellet, n=4
b
islet cell subset BrdU
% % (fold incr.) % (fold incr.) % (fold incr.)
insulin
+ b cells 0.160.0
c 4.660.9 (55
d)0 . 7 60.3 (7) 1.760.3 (19)
glucagon
+ a cells 0.460.1 1.760.5 (3) 4.261.1 (10) 4.162.0 (10)
somatostatin
+ d cells 2.460.7 0.960.3 (0.2) 0.560.3 (0.2) 1.060.3 (0.4)
non-endocr. islet cells
e 0.860.2 7.261.0 (8) 6.160.6 (6) 5.560.6 (6)
CD45+ leucocytes n/a
f 17.562.3 (n/a) 12.861.3 (n/a) 17.562.7 (n/a)
a, baverage random blood glucose during BrdU labeling was (a) 7.6 , and (b) 7.5 mmol/l, respectively (see Supporting Information Table S1).
cBrdU+ cells among specified subset 6S.E.M.
dfold increase of BrdU+ cells over levels of naı ¨ve mice
enon-endocrine cells defined as cells that were CD45-negative and expressed neither insulin, glucagon, or somatostatin.
fnaı ¨ve Rip-CD80
+GP
+ did not contain leukocytic islet infiltrates
doi:10.1371/journal.pone.0004827.t002
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number of certain cell subsets. Taken together these data suggest
that elevated BG levels, occurring when autoimmune diabetes
becomes clinically manifest, specifically and selectively stimulate b-
cell multiplication.
Discussion
Unlike naı ¨ve islets, islets from autoimmune diabetic animals are
composed of much fewer b-cells (and perhaps a-cells, data not
shown) surrounded by vast numbers of leukocytes, some of
which are vigorously proliferating. The typical mouse islet
structure is lost once diabetes is manifest, and these changes
complicate histological analysis. Such challenges include difficul-
ties distinguishing b-cells bound by effector CTLs, or recently
killed, apoptotic b-cell debris found in nearby phagocytes [51].
Moreover, islets within the diseased pancreas display a rather
heterogeneous pattern of lymphocytic infiltration. Flow cytometry
overcomes many of these limitations; and in addition is
quantitative, objective in nature, provides high-throughput
capability, and offers the possibility of simultaneously testing
multiple parameters. Employing multicolor flow cytometry
approaches to dissociated islet cells, we were able to examine the
proliferative properties of the individual endocrine cell subsets
during development of autoimmune diabetes with a precision not
previously achievable. Importantly, we found variable prolifera-
tion in the different islet cell subsets in response to immune-
mediated islet destruction and diabetes development, pointing to
distinct growth regulatory circuits operating on the different islet
cell subsets. We found that only islet b-cell proliferation was tightly
correlated with BG levels.
Numerous in vitro and in vivo models have correlated glycemia
with b-cell mass [16,29,30,52–54]. While b-cells’ proliferative
potential has important therapeutic implications for T1DM [55],
only few experimental studies have probed that proliferative
potential and the factors regulating it during b-cell autoimmunity
[11,25,26,56]. Reasoning from immunohistology obtained during
the pre-diabetic phase in NOD mice, investigators have proposed
that residual b-cell proliferation is controlled by T-mediated islet
inflammation, because b-cell turnover was found to be already
elevated before glycemia control was lost [25,26]. In variance with
these studies, using flow cytometry to test two independent
parameters of cell proliferation, namely total DNA content per cell
and BrdU incorporation, we find using two different diabetes
models (CTL-induced EAD and spontaneous NOD) that mouse b-
cell proliferation is sharply up-regulated coincident with overt
hyperglycemia at disease onset; but much less so in the difficult to
define pre-diabetic disease stages. Our interpretation that elevated
BG levels at disease onset stimulate b-cell proliferation is further
supported by our data showing restored normoglycemia (often
despite unaltered autoimmunity) rapidly lowered b-cell replication
rates to near-normal. We can suggest at least three not-mutually-
exclusive explanations for the slightly higher than normal b-cell
proliferation rates observed in mice with restored glycemia control
after diabetes onset. One, we cannot control exogenous insulin
dosing with the fine specificity required to achieve BG control
close to that achieved by a healthy pancreas; postprandial
hyperglycemia is particularly difficult if not impossible to control
in a mouse. Thus, residual elevated b-cell proliferation rates may
simply reflect pathological glucose tolerance in these mice. Our
islet transplantation results support this idea since previously
diabetic mice that received whole islet grafts reduced b-cell
proliferation virtually to control levels in 5 of 7 mice (Figure 4B),
and did better than subcutaneous pellet-released exogenous
insulin. Two, islet b-cell loss may result not only in insulin
deficiency but also in the loss of other factors important in fine
tuning carbohydrate metabolism, including amylin peptide [57],
glucagon-like peptide 1 or its receptor agonists (reviewed in [58]),
islet-neogenesis-associated-protein [59], activin [60,61], and beta-
cellulin [61], and therefore exogenous insulin may not, on its own,
restore all functions lost when b-cell mass falls below a critical
threshold. Our islet transplantation data support this idea as well.
Three, factors like the local inflammatory environment, organ
injury, and/or net b-cell deficiency may have a metabolism-
independent and direct effect promoting regenerative b-cell
proliferation in the once-diabetic mice. The latter mechanism
was proposed by Sherry et al. [26] who used immunofluorescence
microscopy and image analysis to study NOD mouse b-cells, and
they reported only about a 2-fold increase in ß-cell proliferation in
the mid to late prediabetic phase, but before elevated BG levels
became evident. These authors suggested a prominent role played
by autoaggressive T cells mediating b-cell proliferation in advance
of diabetes onset since they observed reduced b-cell turnover (2–3
fold) up to 6 weeks after Treg or anti-CD3 mAb therapies had
down-regulated aggressive autoimmunity and restored glycemia
control. An alternative explanation might be that the minor
increase in b-cell proliferation we have noticed during the pre-
diabetic phase (Figure 1B, and data not shown) resulted from early
subclinical glucose intolerance.
While in our study both the CTL-induced EAD and the
spontaneous NOD mouse models demonstrated sharply increased
b-cell proliferation rates at diabetes onset, we did note a few
differences between the models. Most notably, NOD mice
responded to exogenous insulin induced normal glycemia by
down-regulating their b-cell proliferation, but with delayed
kinetics compared to the mice with CTL-induced EAD. b-cell
proliferation in diabetic NOD mice (based on BrdU uptake) did
not cease until a few days after glycemia control was restored
(Figure 6). It is of interest that at disease onset, NOD mice have
very few large islets containing virtually all residual b-cells and
these islets are located near the pancreas core ([62] and our
unpublished data), while most islet remnants show either a-, d
cells or only inflammatory cells. It is possible that these giant
islets, not seen in our EAD mice, reflect the slow progression of
islet autoimmunity in NOD mice, and could account for the
delayed adjustment of b-cell proliferation after restoration of
normal BG levels. It is further possible that the survival of residual
ß-cells results from a more favorable balance in individual islets
between effector lymphocytes and immune regulatory mecha-
nisms, which locally allows b-cells to survive and sustain
proliferation, and over time can grow to large islet structures. In
this environment, abrupt (therapeutic) changes in BG levels
perhaps do not translate into an immediate halt of b-cell turnover.
In fact, continuous exogenous insulin (pellets) more frequently
caused hypoglycemia in diabetic NOD in the first few days after
treatment, and rarely in EAD mice (data not shown). Hypogly-
cemia may reflect an additive effect in the NOD mouse of
exogenous insulin and temporarily continuing b-cell replication in
a glucose-resistant fashion.
In conclusion, we propose a scenario in which hyperglycemia
at clinical disease manifestation drives an increase in b-cell mass,
mediated to a large extent by residual b-cell proliferation. Even
though such newly generated b-cells would be subject to
immune rejection, our data could imply a temporary net gain in
b-cells at disease onset which might explain or contribute to
the reduced insulin requirements patients typically experience
shortly after T1DM diagnosis, commonly known as ‘‘honeymoon’’
[13]. The honeymoon’s transience may result from the exhaus-
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unchecked anti-b-cell autoimmune response. Such a view would
emphasize the potential of spontaneous recovery should the
immune response be permanently halted at this clinically
prominent stage.
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